| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
208.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $22.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
53,265 |
53,265 |
74,223 |
229,905 |
| Total Sell Value |
$339,844 |
$339,844 |
$555,147 |
$3,944,931 |
| Total People Sold |
3 |
3 |
4 |
13 |
| Total Sell Transactions |
3 |
3 |
5 |
43 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gut Robert |
Chief Medical Officer |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,380 |
45,875 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-02-19 |
4 |
AS |
$63.05 |
$484,256 |
D/D |
(7,501) |
284,753 |
|
-30% |
|
| Soteropoulos Paula |
Director |
– • – |
2020-02-05 |
4 |
AS |
$60.58 |
$129,332 |
D/D |
(2,122) |
2,423 |
|
6% |
|
| Gut Robert |
Chief Medical Officer |
• • – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,610 |
33,495 |
|
- |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,610 |
46,710 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,713 |
292,254 |
|
- |
|
| Van Deventer Sander |
EVP, Research & Product Dev. |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,092 |
49,219 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,201 |
48,765 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-01-31 |
4 |
AS |
$57.98 |
$224,499 |
D/D |
(3,872) |
264,541 |
|
7% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-01-30 |
4 |
AS |
$58.74 |
$1,398,646 |
D/D |
(23,583) |
268,413 |
|
6% |
|
| Astley-Sparke Philip |
Director |
– • – |
2020-01-30 |
4 |
S |
$59.23 |
$47,799 |
D/D |
(807) |
6,005 |
|
-6% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-01-29 |
4 |
AS |
$61.55 |
$1,460,794 |
D/D |
(23,583) |
291,996 |
|
2% |
|
| Kaye Jack |
Director |
– • – |
2020-01-28 |
4 |
S |
$62.20 |
$50,133 |
D/D |
(806) |
14,128 |
|
-1% |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2020-01-28 |
4 |
S |
$61.08 |
$91,848 |
D/D |
(1,478) |
40,100 |
|
-1% |
|
| Soteropoulos Paula |
Director |
– • – |
2020-01-28 |
4 |
S |
$62.19 |
$50,187 |
D/D |
(807) |
4,545 |
|
-1% |
|
| Schaffer David |
Director |
– • – |
2020-01-28 |
4 |
S |
$62.27 |
$50,190 |
D/D |
(806) |
44,915 |
|
-1% |
|
| Van Deventer Sander |
EVP, Research & Product Dev. |
• – – |
2020-01-28 |
4 |
S |
$61.27 |
$137,214 |
D/D |
(2,227) |
43,127 |
|
-1% |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2020-01-28 |
4 |
S |
$61.28 |
$736,072 |
D/D |
(11,975) |
42,564 |
|
-1% |
|
| Balachandran Madhavan |
Director |
– • – |
2020-01-28 |
4 |
S |
$62.20 |
$50,195 |
D/D |
(807) |
6,005 |
|
-1% |
|
| Springhorn Jeremy P. |
Director |
– • – |
2020-01-28 |
4 |
S |
$60.94 |
$50,190 |
D/D |
(807) |
6,005 |
|
-1% |
|
| Meek David D. |
Director |
– • – |
2020-01-28 |
4 |
S |
$60.94 |
$44,903 |
D/D |
(722) |
2,508 |
|
-1% |
|
| Gut Robert |
Chief Medical Officer |
• – – |
2020-01-28 |
4 |
AS |
$62.19 |
$37,065 |
D/D |
(596) |
27,885 |
|
1% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-01-28 |
4 |
AS |
$61.24 |
$1,460,221 |
D/D |
(23,583) |
315,579 |
|
1% |
|
| Gut Robert |
Chief Medical Officer |
• – – |
2020-01-27 |
4 |
AS |
$60.01 |
$413,889 |
D/D |
(6,897) |
28,481 |
|
-5% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-01-27 |
4 |
AS |
$59.87 |
$1,854,280 |
D/D |
(28,289) |
339,162 |
|
-5% |
|
336 Records found
|
|
Page 9 of 14 |
|
|
0.01 (0.21%) 
